Although genetic factors contribute to almost half of all cases of deafness, treatment options for genetic deafness are limited 1-5 . We developed a genome-editing approach to target a dominantly inherited form of genetic deafness. Here we show that cationic lipid-mediated in vivo delivery of Cas9-guide RNA complexes can ameliorate hearing loss in a mouse model of human genetic deafness. We designed and validated, both in vitro and in primary fibroblasts, genome editing agents that preferentially disrupt the dominant deafness-associated allele in the Tmc1 (transmembrane channellike gene family 1) Beethoven (Bth) mouse model, even though the mutant Tmc1
mice substantially reduced progressive hearing loss. We observed higher hair cell survival rates and lower auditory brainstem response thresholds in injected ears than in uninjected ears or ears injected with control complexes that targeted an unrelated gene. Enhanced acoustic startle responses were observed among injected compared to uninjected Tmc1 Bth/+ mice. These findings suggest that protein-RNA complex delivery of target gene-disrupting agents in vivo is a potential strategy for the treatment of some types of autosomaldominant hearing loss.
Although about 100 deafness-associated alleles have been identified, few treatments are available to slow or reverse genetic deafness 4, 5 . Complementation of wild-type alleles, or silencing of dominant-negative mutant alleles, have shown promising results in animal models 6, 7 . Nonetheless, current approaches face potential challenges including immunogenicity, oncogenicity, and limitations of viral vectors 8, 9 . Cas9-based genome editing agents can mediate targeted gene disruption or repair [10] [11] [12] [13] . For applications that seek a one-time, permanent modification of genomic DNA, the delivery of non-replicable, transient Cas9-single guide RNA (sgRNA) ribonucleotide protein (RNP) complexes in vivo offers improved DNA specificity and potentially greater safety and applicability 14, 15 , compared with methods that introduce DNA expressing these agents. Approximately 20% of alleles associated with genetic deafness are dominantly inherited 1 . As Cas9-sgRNA complexes can efficiently disrupt genes through end-joining processes, we sought to design Cas9-sgRNA complexes that selectively disrupt dominant alleles associated with hearing loss.
Many genes linked to genetic hearing loss affect the function of sensory hair cells, which transduce acoustic vibrations into electrical nerve signals. TMC1 is an essential component of mechanotransduction channels in mammalian hair cells 16 . Mutations in TMC1 have been linked to recessive and dominant genetic deafness in humans 17 .
A dominant-negative missense mutation in TMC1 (p.M418K, c.T1253A) causes reduced single-channel current levels and calcium permeability 16 in hair cells, and progressive post-lingual sensorineural hearing loss in humans [18] [19] [20] . The Tmc1
Bth/+ mouse model carries the orthologous missense mutation (p.M412K, c.T1235A) in the mouse Tmc1 gene and exhibits progressive elevation of the auditory response threshold and progressive hair cell loss beginning at one month of age 21 .
As the orthologous mutations in human and mouse both cause progressive, profound hearing loss, the Tmc1
Bth/+ mouse is a promising model for the development of treatment strategies 21 .
We began by developing a genome editing strategy that preferentially disrupts the mouse mutant Tmc1
Bth allele. To distinguish the mutant and wild-type alleles, we identified sgRNAs that target Tmc1 at sites that include the T1235A mutation and a nearby NGG protospaceradjacent motif (PAM) sequence required by Streptococcus pyogenes Cas9. We identified three candidate sgRNAs (Tmc1-mut1, Tmc1-mut2 and Tmc1-mut3) that place the Bth mutation at position 11, 12, and 15, respectively, of the spacer, counting the PAM as positions [21] [22] [23] (Fig. 1a) . Mismatches between the sgRNA and genomic DNA that are close to the PAM are poorly tolerated by Cas9 10 , increasing the likelihood that the Bth mutant allele will be selectively edited. A fourth sgRNA, Tmc1-mut4, is a truncated version of Tmc1-mut3 designed to increase genome editing DNA specificity 22 . We evaluated the ability of these four sgRNAs in complex with Cas9 to cleave either the wild-type Tmc1 or the Tmc1 Bth allele in vitro. All sgRNAs tested comparably or preferentially cleaved the Tmc1
Bth allele, with Tmc1-mut3 exhibiting the greatest selectivity (Extended Data Fig. 1a, b) .
We performed lipid-mediated delivery of Cas9-sgRNA RNP complexes into cultured primary fibroblasts derived from wild-type or homozygous Tmc1
Bth/Bth mice to evaluate the allele specificity of genomic DNA modification in mouse cells. We delivered Cas9 complexed with each of the four sgRNAs using Lipofectamine 2000 into both wild-type and Tmc1
Bth/Bth mutant fibroblasts. RNP delivery into these primary fibroblasts was twofold to fourfold less efficient than with HEK293T cells (Extended Data Fig. 1c ). The highest rate of targeted insertions and deletions (indels) in mutant Tmc1
Bth/Bth fibroblasts (10%) was observed with Cas9-Tmc1-mut3 RNPs, while lower indel frequencies (0.74-4.1%) were observed using the other sgRNAs (Fig. 1b) .
. We used both the GUIDE-seq method 23 and computational prediction 24 to identify potential off-target loci that could be modified by exposure to Cas9-Tmc1-mut3. Ten off-target sites containing up to six mismatches in the protospacer region of Tmc1-mut3 sgRNA were identified by GUIDEseq (Extended Data Fig. 3a) . None of these off-target loci are known to be associated with hearing function (Extended Data Table 1a ). We measured the indel frequency at each off-target site by high-throughput sequencing (HTS) in Tmc1
Bth/Bth primary mouse fibroblasts treated with Cas9-Tmc1-mut3 following plasmid DNA nucleofection or RNP delivery. Plasmid nucleofection resulted in 0.68-8.1% indels at nine of the ten GUIDE-seq-identified off-target sites (Extended Data Fig. 3b and Extended Data Table 1a ). By contrast, after RNP delivery, modification of only one off-target site (off-T1, 1.2% indels) was detected (Extended Data Fig. 3b ), consistent with our earlier findings that RNP delivery greatly reduces off-target editing compared with DNA delivery 15 . Among the computationally predicted off-target sites 24 , only the two (off-T1′ and off-T2′) that were also identified as off-targets by GUIDE-seq were observed to undergo modification (Extended Data Table 1b ). Together, these results suggest that delivery of Cas9-Tmc1-mut3 RNP complexes into Tmc1
Bth/Bth cells leads to mini mal off-target modification, and that phenotypes affecting hearing are unlikely to arise from off-target modification.
To evaluate the ability of the Cas9-Tmc1-mut3 sgRNA complex to target the Tmc1
Bth allele in hair cells in vivo, we complexed Cas9-Tmc1-mut3 sgRNA with Lipofectamine 2000 and injected the resulting mixture into the scala media of neonatal mice by cochleostomy. Neonatal cochlear hair cells produce TMC1 and TMC2, both of which can enable sensory transduction. To isolate the effect of editing the Tmc1
Bth allele, we injected the Cas9-Tmc1-mut3 sgRNA-lipid complex into Tmc1
, to avoid transduction current contributions from TMC2 or wild-type TMC1. We recorded sensory transduction currents from inner hair cells (IHCs) after injection with the Cas9-Tmc1-mut3-lipid complex, or with a control targeting an unrelated Gfp gene. We observed a significant decline in transduction current amplitudes in Tmc1
Tmc2
Δ/Δ mice following injection with Cas9-Tmc1-mut3-lipid complexes, consistent with disruption of the Tmc1
Bth allele in sensory hair cells in vivo, but not with Cas9-GFP sgRNA-lipid complexes (Fig. 2a, b) .
In Tmc1 Bth/+ Tmc2 +/+ mice (referred to hereafter as Tmc1
Bth/+ mice), IHCs undergo progressive death, followed by the outer hair cells (OHCs) 21 . To determine the effect of Cas9-Tmc1-mut3 sgRNA on Tmc1
Bth/+ hair cell survival, we injected Cas9-Tmc1-mut3-lipid complex into the scala media of mice on postnatal day 1 (P1) and removed the injected and uninjected cochleae after eight weeks. Uninjected ears exhibited substantial loss of IHCs and partial degeneration of OHCs (Fig. 2c, f, g ) compared with wild-type ears (C3HeB/ FeJ (C3H) mice, which are the genetic background of the Tmc1 Bth/+ mice) (Fig. 2e) . In injected ears, survival of IHCs and OHCs was significantly enhanced (Fig. 2d, f, g ). Stereocilia bundles were observed on surviving IHCs in injected ears, but were absent in uninjected ears in the basal and middle turns (Extended Data Fig. 4a ). These results suggest that Cas9-Tmc1-mut3-lipid injection in vivo promotes hair cell survival in Tmc1
Bth/+ mice. The strong differences between treated and untreated ears suggests that sporadic disruption of Tmc1
Bth may benefit not only edited hair cells, but also surrounding hair cells, consistent with previous findings 25 .
To study the effect of Cas9-Tmc1-mut3-lipid injection on cochlear function in Tmc1
Bth/+ mice, we measured auditory brainstem responses (ABRs), which represent the sound-evoked neural output of the cochlea, as well as distortion product otoacoustic emissions (DPOAEs), which measure the amplification provided by OHCs 21 .
In uninjected ears of Tmc1
Bth/+ mice, we observed profound attenuation of cochlear neural responses, with ABR thresholds ranging from 70-90 dB at four weeks of age, compared with 30-50 dB for wild-type C3H mice ( Fig. 3a and Extended Data Fig. 4b ). The elevations in DPOAE thresholds at this time in Tmc1
Bth/+ mice were smaller than the elevations in ABR threshold (Extended Data Fig. 5a ), consistent with reports that IHCs are more severely affected than OHCs in Tmc1
Bth/+ mice 21 . Four weeks after Cas9-Tmc1-mut3-lipid injection, treated Tmc1
Bth/+ ears showed substantially enhanced cochlear function, with lower ABR thresholds relative to uninjected ears at all frequencies below 45 kHz (Fig. 3a ). Significant (P ≤ 0.001) hearing preservation was detected from 8 to 23 kHz, with average ABR thresholds 15 dB lower for treated ears than untreated contralateral ears ( Fig. 3a; Supplementary Table 1 ). DPOAE thresholds were slightly elevated in the injected ears, consistent with OHC damage, perhaps from the injection procedure (Extended Data Fig. 5 ). We also observed greater ABR wave 1 amplitudes, and a more normal Targeted region of the Tmc1 Bth allele   Tmc1-mut1   Tmc1-mut4   1,235   Tmc1-mut2  Tmc1-mut3   Tmc1-mut4: 5′--3′   Tmc1-mut1: 5′--3′   Tmc1-mut3: 5′--3′   PAM   5′--3′  3′--5′   b Tmc1-mut1 Tmc1-mut2 Tmc1-mut3 Tmc1-mut4 Untreated Bth -targeting sgRNA contains a complementary T (red) that pairs with the T1235A mutation in the Tmc1
Bth allele, but that forms a mismatch with the wild-type Tmc1 allele. b, Lipid-mediated delivery of Cas9-sgRNA complexes into primary fibroblasts derived from wild-type or homozygous Tmc1
Bth/Bth mice. Purified Cas9 protein (100 nM) and 100 nM of each sgRNA shown were delivered using Lipofectamine 2000. Indels were quantified by HTS. Individual values (n = 3-6) are shown; horizontal lines and error bars represent the mean values ± s.d. of three or more independent biological replicates.
Letter reSeArCH 1 1 j a n u a r y 2 0 1 8 | V O L 5 5 3 | n a T u r E | 2 1 9 ABR waveform pattern, in injected ears than in uninjected controls (Fig. 3b, c) . Together, these results show that injection of neonatal Tmc1
Bth/+ mice with Cas9-Tmc1-mut3-lipid complexes reduces progressive hearing loss.
To test whether amelioration of hearing loss requires the mutant Tmc1
Bth allele-specific sgRNA, we injected Cas9-Tmc1-wt3-lipid complexes targeting the wild-type Tmc1 allele rather than the Tmc1
Bth mutant allele into P1-2 Tmc1
Bth/+ mice. After four weeks, ABR thresholds in the injected ears were similar to, or worse than, those in the contralateral uninjected ears (Extended Data Fig. 6a Fig. 6f, g ). Collectively, these results establish that hearing preser vation depends on sgRNA allele specificity, Cas9 DNA cleavage activity, and the presence of the Tmc1 Bth allele. We also characterized the cochlear function of Tmc1
Bth/+ mice eight weeks after treatment. Mean ABR thresholds following Cas9-Tmc1-mut3-lipid injection remained lower than uninjected controls from 5.7-23 kHz, although the average improvement was lower than at four weeks post-treatment (Extended Data Fig. 4c, d ), potentially owing to continued progressive hearing loss in the non-edited hair cells.
As a behavioural measure of hearing rescue, we assessed acoustic startle responses eight weeks after injection. In uninjected Tmc1
Bth/+ mice, no startle response was detected following stimulation at 120 dB. By contrast, significant startle responses were detected in Cas9-Tmc1-mut3-lipid-injected Tmc1
Bth/+ mice following stimulus at 110 and 120 dB ( Fig. 3d and Extended Data Fig. 4e ), demonstrating that hearing preservation upon treatment also preserves an acoustic behavioural reflex.
To evaluate the ability of each of the other Tmc1
Bth -targeting sgRNAs to mediate hearing rescue in vivo, we also injected Tmc1-mut1, Tmc1-mut2, and Tmc1-mut4 complexed with Cas9 into neonatal Tmc1
Bth/+ cochleae, and observed varying degrees of enhanced cochlear function (Extended Data Fig. 7) . Thus, while Tmc1-mut3 resulted in the most robust hearing preservation, other sgRNAs targeting the mutant Bth allele also partially preserved cochlear function.
To test whether RNP delivery of editing agents in adult mouse inner ears supports genome editing in hair cells, we injected Cas9-GFP sgRNA-lipid complexes into the cochleae of six-week-old Atoh1-GFP Letter reSeArCH mice by canalostomy. Two weeks after injection, loss of GFP fluorescence in the apical turn suggested target gene disruption with 25 ± 2.1% efficiency (Extended Data Fig. 8 ), comparable to previous observations of 20% GFP editing in neonatal hair cells 15 . These results suggest that this approach may be applicable to dominant genetic deafness that manifests with late-onset hearing loss.
To confirm that in vivo treatment of Tmc1 Bth/+ mice with Cas9-Tmc1-mut3 sgRNA disrupted the Tmc1
Bth allele, we sequenced DNA from cochlea tissue collected from injected Tmc1
Bth/+ and untreated
Tmc1
Bth/+ mice. After injection on P1, tissues were removed on P5 and separated into organ of Corti (containing hair cells), spiral ganglion, and spiral ligament samples (Extended Data Fig. 9a, b) . We estimated the fraction of hair cells in dissected cochlear tissue to be only about 1.5% of the total cells used for DNA sequencing (Extended Data Fig. 9a, b) . Nevertheless, we observed unambiguous indels at the Tmc1 Bth locus in cochlear tissue from treated mice (Fig. 4a) . The organ of Corti samples contained, on average, Tmc1 editing of 0.92% of total sequenced DNA, which corresponds to about 1.8% Tmc1
Bth allele disruption in the heterozygous mice (Fig. 4a) . We also isolated samples of much smaller numbers of cells (up to a few dozen, mostly hair cells) from Bth mutation is shown in red. treated mice. Decreasing the number of cells entering the genomic DNA amplification and sequencing process increased the observed editing percentage to as high as 10% Tmc1
Bth allele disruption, but also elevated background Tmc1 indel rates of untreated mice to an average of 0.82 ± 0.57% and a maximum of 1.6%, probably reflecting increased noise from processing of minute quantities of genomic DNA. No indel frequencies above that of untreated controls at any of the above-identified off-target sites were observed in Cas9-Tmc1-mut3-lipid-treated tissues (Extended Data Fig. 9c) . Together, these observations confirm that Cas9-Tmc1-mut3-lipid treatment in vivo edits the Tmc1 locus with no detected editing at GUIDE-seq-identified off-target loci.
An analysis of indel-containing Tmc1 sequencing reads from treated Tmc1
Bth/+ mice allowed us to directly assess the allele specificity of Cas9-Tmc1-mut3 in vivo. Of 11,694 sequencing reads containing indels from four treated organ of Corti samples, 6,118 (52%) contained an intact nucleotide at Tmc1 position 1,235. Of these, 5,736 (94%) contained modification of the mutant Tmc1
Bth allele, whereas only 382 (6%) contained modification of the wild-type Tmc1 allele (Fig. 4b) . Therefore, samples after treatment on average contained 15-fold higher modification of the Tmc1
Bth allele over the wild-type allele (Fig. 4b, c ). These results demonstrate selective disruption of the Tmc1
Bth allele in Tmc1
Bth/+ mice, consistent with observed hearing phenotypes, even though the Tmc1
Bth and wild-type Tmc1 alleles differ only at a single base pair.
This work shows that cationic lipid-mediated Cas9-sgRNA complex delivery in vivo can achieve allele-specific gene disruption in a mouse model of a human genetic disease, resulting in amelioration of the disease phenotype. Our results suggest that this approach has potential for the treatment of autosomal-dominant hearing loss related to hair cell dysfunction, and provide a complementary strategy to other approaches that use antisense oligos (ASOs) or RNA interference 6, 25 . The genome editing strategy developed here may inform the future development of a DNA-free, virus-free, one-time treatment for certain genetic hearing loss disorders.
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Letter reSeArCH MethODS

Primary cell culture. Wild-type, Tmc1
Bth/+ and Tmc1 Bth/Bth fibroblasts were obtained from P5 pups (see below). Mice were euthanized and cleaned with 70% ethanol. Underarm skin fragments (1-2 cm 2 ) were excised and submerged in cold HBSS (ThermoFisher). Subcutaneous fat was removed by forceps. Skin fragments were cut into ~1-mm 2 pieces with a 25G 5/8′′ syringe (1180125058, Covidien). Tissues were digested with 0.5 mg/ml Liberase DL (Sigma 5401160001) at 37 °C for 1 h with occasional pipetting up and down to break cell clumps. Warm culture medium (1:1 DMEM:F12 medium (ThermoFisher) with 15% fetal bovine serum (FBS) (ThermoFisher) and 100 U/ml penicillin+streptomycin (ThermoFisher) was added to stop the enzyme digestion. The solution was filtered with a 70-μm cell strainer (Falcon) and centrifuged at 200g for 5 min. The pellet was resuspended in culture medium and transferred to a 25-ml culture flask, then incubated at 37 °C with 5% CO 2 and 3% O 2 . Fibroblasts were cultured for about 2-3 days to reach ~90% confluence, then passaged in 100-ml flasks in DMEM plus GlutaMax (ThermoFisher) supplemented with 10% (v/v) FBS at 37 °C with 5% CO 2 . Delivery of proteins complexed with cationic lipids into mouse fibroblasts. Cultured fibroblast cells were plated in 24-well format (500 μl well volume) in Dulbecco's modified Eagle's medium plus GlutaMAX (DMEM, Life Technologies) with 10% FBS (no antibiotics) at a cell density sufficient to reach ~80% confluence at the time of usage. Purified sgRNA was incubated with Cas9 protein for 5 min before complexing with cationic lipid 15, 26 . Delivery of Cas9-sgRNA was performed by combining 100 nM RNP complex with 3 μl cationic lipid in 50 μl OPTIMEM medium (Life Technologies) according to the manufacturer's protocol for DNA plasmid transfection. The above mixture containing cationic lipid and RNP was then added to cells. All complexing steps were performed at room temperature. Cells were harvested and genomic DNA was extracted for sequencing ~96 h after treatment. GUIDE-seq and data analysis. Mouse fibroblasts were transfected using 1,000 ng Cas9 plasmid (pCas9), 300 ng sgRNA plasmid (pTmc1-mut3 sgRNA), and 50 pmol GUIDE-seq double-stranded oligodeoxynucleotides (dsODN) using a LONZA 4D-Nucleofector. Transfection programs were optimized following the manufacturer's instructions (CA158 and CA189, P2 Primary Cell 4D-Nucleofector X Kit). pmaxGFP Control Vector (400 ng; LONZA) was added to the nucleofection solution to assess nucleofection efficiency in primary cells. The medium was replaced ~16 h after nucleofection and cells were collected for genomic DNA extraction after ~96 h. For GUIDE-seq off-target DNA cleavage analysis, pCas9, pTmc1-mut3 sgRNA, pmaxGFP, and dsODN were nucleofected into Tmc1
Bth/+ heterozygous mouse primary fibroblasts. A sample nucleofected with dsODN only served as a negative control. About 400 ng genomic DNA for each sample was sheared acoustically using a Covaris m220 sonicator to an average length of 500 bp in 130 μl TE buffer. Each sample was sequenced on an Illumina Miseq following previously described protocols 23 . Reads were consolidated first by their Illumina indexes and then by the 8-nt molecular index that defines a single pre-PCR template fragment. The consolidated reads were mapped to the mouse reference genome (GRCm38) using BWA-MEM. Off-target sites were identified by first mapping the start position of the amplified sequences using a 10-bp sliding window, then retrieving the reference sequence around the site. Given the size of some of the deletions, the number of base pairs used as the flanking sequence was increased to 100 bp. The retrieved sequences were aligned to the Cas9 target sequence using a SmithWaterman local-alignment algorithm. High-throughput DNA sequencing of genomic DNA samples. Treated cells or tissues were collected after four days and genomic DNA was isolated using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter) according to the manufacturer's instructions. On-target and off-target genomic regions of interest were amplified by PCR with flanking HTS primer pairs (listed in Supplementary Sequences). PCR amplification was carried out with Phusion high-fidelity DNA polymerase (ThermoFisher) according to the manufacturer's instructions using ~100 ng genomic DNA as a template. PCR cycle numbers were chosen to ensure the reaction was stopped during the log-linear range of amplification. PCR products were purified using RapidTips (Diffinity Genomics). Purified DNA was amplified by PCR with primers containing sequencing adaptors. The products were purified by gel electrophoresis and quantified using the Quant-iT TM PicoGreen dsDNA Assay Kit (ThermoFisher) and KAPA Library Quantification Kit-Illumina (KAPA Biosystems). Samples were sequenced on an Illumina MiSeq as previously described 27 . Sequencing reads were demultiplexed using MiSeq Reporter (Illumina), and individual FASTQ files were analysed with a custom Matlab script (Supplementary Note). Each read was pairwise aligned to the appropriate reference sequence using the Smith-Waterman algorithm. Base calls with a Q-score below 31 were excluded from calculating editing frequencies. Sequencing reads were scanned for exact matches to two 10-bp sequences that flank both sides of a window in which indels might occur. If no exact matches were located, the read was excluded from analysis. If the length of this indel window exactly matched the reference sequence, the read was classified as not containing an indel. If the indel window was one or more bases longer or shorter than the reference sequence, then the sequencing read was classified as an insertion or deletion, respectively. Bth/+ or C3H mice (P0-2) of either sex were used for injections. The mice were randomly assigned to the different experimental groups. The final 25% of the experiments were performed in a double-blinded manner. At least five mice were injected in each group. All surgical procedures were done in a clean, dedicated space. Instruments were thoroughly cleaned with 70% ethanol and autoclaved before surgery. Fresh Cas9 and sgRNA were mixed before injection at a final concentration of 25 μM. One microlitre Lipofectamine 2000 was mixed with 1 μl Cas9-sgRNA RNP and incubated for 20 min at room temperature. Mice were anaesthetized by hyperthermia on ice. Cochleostomy was performed by preauricular incision to expose the cochlear bulla. Anatomical landmarks included the stapedial artery and tympanic ring, which were identified before injection. Glass micropipettes (4878, WPI) were pulled with a micropipette puller (PP83, Narishige) to a final outer diameter of ~10 μm. Needles held by a Nanolitre 2000 micromanipulator (WPI) were used to manually deliver the Cas9-sgRNA-lipid complexes into the scala media, which allows access to inner ear cells. The injection sites were the base, middle, and apex-middle turn of the cochlea. The volume for each injection was 0.3 μl with a total volume of 0.9 μl per cochlea. The release rate was 69 nl/min, controlled by a MICRO4 microinjection controller (WPI). Microinjection into adult inner ear by canalostomy. Three 6-week-old Atoh1-GFP mice 28 were injected with Cas9-GFP sgRNA-lipid complex, with the same concentration and volume for each component as used in injection into neonatal inner ear. Mice were anaesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100 mg/kg). The right post-auricular region was exposed by shaving and disinfected with 10% povidone iodine. For canalostomy, a 10-mm postauricular incision was made under the operating microscope, and the right pinna and the sternocleidomastoid muscle were extracted to expose the posterior semicircular canal (PSCC), located in the margin of the temporal bone. We used a Bonn microprobe (Fine Science Tools) to drill a small hole on the PSCC, then left it open for a few minutes until no obvious perilymph leakage was observed. The tip of the polyimide tube (inner diameter 0.0039 inches, outer diameter 0.0049 inches, Microlumen) was inserted into the PSCC towards the ampulla. The hole was sealed with tissue adhesive (3M Vetbond), and a lack of fluid leakage indicated the tightness of the sealing. The tubing was cut after injection, with approximately 5 mm of tubing left connected to the PSCC and sealed with tissue adhesive. The volume for each injection was 1 μl per cochlea. The release rate was 169 nl/min, controlled by MICRO4 microinjection controller (WPI). The skin was closed with 5-0 nylon suture (Ethicon Inc.). The total surgery time was approximately 20 min, including a 6-min injection period. Acoustic testing. ABR and DPOAE were recorded as described previously 29 at 32 °C in a soundproof chamber. Mice of either sex were anaesthetized with xylazine (10 mg/kg, intraperitoneally (i.p.)) and ketamine (100 mg/kg, i.p.). Acoustic stimuli were delivered through a custom acoustic assembly consisting of two miniature dynamic electrostatic earphones (CDMG15008-03A, CUI) to generate primary tones and a miniature microphone (FG-23329-PO7, Knowles) to record ear-canal sound pressure near the eardrum. Custom LabVIEW software controlling National Instruments 24-bit soundcards (6052E) generated all ABR and DPOAE stimuli and recorded all responses.
For ABR measurements, needle electrodes were inserted at the vertex and ventral edge of the pinna, with a ground reference near the tail. ABR potentials were evoked with 5-ms tone pips (0.5-ms rise-fall with a cos2 onset, delivered at 35/s). The response was amplified 10,000-fold, filtered (100 Hz-3 kHz passband), digitized, and averaged (1,024 responses) at each SPL. The sound level was raised in 5 dB steps from 30 dB below threshold up to 90 dB SPL at frequencies from 5.66-45.24 kHz (in half-octave steps). Following visual inspection of stacked waveforms, "threshold" was defined as the lowest sound pressure level (SPL) at which any wave could be detected. In general, thresholds were defined by three independent observers. Wave 1 amplitude was defined as the difference between the average of the 1-ms pre-stimulus baseline and the wave 1 peak (P1), after additional high-pass filtering to remove low-frequency baseline shifts.
For DPOAE measurements, the cubic distortion product was measured in response to primaries f1 and f2. The primary tones were set so that the frequency ratio (f2/f1) was 1.2 and so that the f2 level was 10 dB below the f1 level. For each f2/f1 primary pair, primaries were swept in 5-dB steps from 20 dB SPL to 80 dB SPL (for f2). At each level, the amplitude of the DPOAE at 2f1-f2 was extracted from the averaged spectra, along with the noise floor. Threshold was computed by interpolation as the f2 level required to produce a DPOAE at 5 dB SPL. Acoustic startle reflex. Mice were placed into a small, acoustically transparent cage resting atop a piezoelectric force plate in a sound attenuated booth. Acoustic stimuli and amplified force plate signals were encoded by a digital signal processor (Tucker-Davis Technologies, RX6) using LabView scripts (National Instruments). Mice were placed in silence for 2 min and 60 dB broadband white noise for 5 min to acclimate to the test environment before real measurements. Broadband white noise was presented at a background level of 60 dB SPL throughout the experiment and a 16-kHz tone was presented at randomized intervals from an overhead speaker (80 dB to 120 dB SPL, 20 ms duration with 0 ms onset and offset ramps). Ten repetitions were recorded for each of the intensities per test subject. Startle response amplitude was measured as the root mean square (RMS) voltage of the force plate signal shortly after sound presentation. Immunohistochemistry and histology. Injected and non-injected cochleae were removed after animals were killed by CO 2 inhalation. Temporal bones were fixed in 4% paraformaldehyde at 4 °C overnight, then decalcified in 120 mM EDTA for at least 1 week. The cochleae were dissected in pieces from the decalcified tissue for whole-mount immunofluorescence. Tissues were infiltrated with 0.3% Triton X-100 and blocked with 8% donkey serum for 1 h before applying the first antibody. Rabbit anti-MYO7A (1:500 ; #25-6790, Proteus BioSciences), chicken anti-GFP (1:750; ab13970, Abcam) and goat anti-SOX2 (1:350; sc-17320, Santa Cruz Biotechnology) were used at room temperature overnight. The second antibody was incubated for 1 h after three rinses with PBS rinses. All Alexafluor secondary antibodies were from Invitrogen: donkey anti-rabbit Alex488 (A21206) or Alex 594 (A21207), donkey anti goat Alex594 (A11058) or Alexa-488-phalloidin (A12379) and goat anti-chicken Alex488 (A-11039) were used at a 1:500 dilution. Specimens were mounted in ProLong Gold Antifade Mountant medium (P36930, Life Technologies). Confocal images were taken with a Leica TCS SP5 microscope using a 20× or 63× glycerin-immersion lens, with or without digital zoom. For IHC and OHC counting, we acquired z-stacks by maximum intensity projections of z-stacks for each segment by imageJ (NIH image), and composite images showing the whole cochlea were constructed in Adobe Photoshop CS3 to show the whole turn of cochlea. A frequency map was constructed for each case by measuring the spiral extent of all the dissected cochlear pieces and converting cochlear location to frequency using a plug-in of ImageJ (https://www.masseyeandear.org/ research/otolaryngology/investigators/laboratories/eaton-peabody-laboratories/ epl-histology-resources/imagej-plugin-for-cochlear-frequency-mapping-inwhole-mounts). MYO7A-positive IHCs and OHC were counted in the cochlear regions that respond to different sound frequencies, and any segments containing dissection-related damage were omitted from further analysis.
Hair cell transduction current recording. Wild-type or Tmc1
Bth/Δ Tmc2
littermates were injected with 0.9 μl Cas9-Tmc1-mut3-Lipofectamine 2000 or Cas9-GFP sgRNA-Lipofectamine 2000. Wild-type C57B/L6 mice were injected with 0.9 μl Cas9-Tmc1-wt3-Lipofectamine 2000 at P0-P1 via cochleostomy. Cochleae were removed at P5-P6 and cultured in MEM(1×) + GlutaMAX-I medium with 1% FBS at 37 °C, 5% CO 2 for up to 15 days. For recording, the organs of Corti were bathed in standard artificial perilymph containing 137 mM NaCl, 0.7 mM NaH 2 PO 4 , 5.8 mM KCl, 1.3 mM CaCl 2 , 0.9 mM MgCl 2 , 10 mM HEPES, and 5.6 mM d-glucose. Vitamins (1:50) and amino acids (1:100) were added to the solution from concentrates (Invitrogen, ThermoFisher Scientific), and NaOH was used to adjust the final pH to 7.4 (~310 mOsm/kg). Recording pipettes (2-4 MΩ)
were pulled from R6 capillary glass (King Precision Glass) and filled with intracellular solution containing 135 mM CsCl, 5 mM HEPES, 5 mM EGTA, 2.5 mM MgCl 2 , 2.5 mM Na 2 -ATP, and 0.1 mM CaCl 2 ; CsOH was used to adjust the final pH to 7.4 (~285 mOsm/kg). Whole-cell, tight-seal, voltage-clamp recordings were conducted at −84 mV at room temperature (22-24 °C) with an Axopatch 200B amplifier (Molecular Devices). Hair bundles were deflected with a stiff glass probe fabricated from capillary glass with a fire polisher (MF-200, World Precision Instruments) to create a rounded probe tip of ~3-5 μm in diameter. Probes were mounted on a PICMA Chip piezo actuator (Physik Instrument) and driven by an LVPZT amplifier (E-500.00, Physik Instrumente). Sensory-transduction currents were recorded from uninjected and Cas9-sgRNA-treated hair cells. The data were filtered at 10 kHz with a low-pass Bessel filter and digitized at >20 kHz with a 16-bit acquisition board (Digidata 1440A, Molecular Devices) and pClamp 10 software (Molecular Devices).
Inner ear tissue dissection for HTS. Tmc1
Bth/+ mice were injected with Cas9-sgRNA at P1 as described above. All dissection instruments were thoroughly cleaned with 70% ethanol and DRNAase Free (D6002, ARgos), then autoclaved before dissection. Mice were euthanized at P5. Temporal bones were removed and immersed in clean PBS pH 7.4 (10010001, ThermoFisher) individually. Different forceps were used for each ear. The organ of Corti, spiral ganglion, and spiral ligament from the injected and non-injected ear, and tail tissue were all removed under microscope from each mouse.
Hair cells isolation for HTS. Tmc1
Bth/+ mice were injected with Cas9-Tmc1-mut3-Lipofectamine 2000 at P1 and euthanized at P5. Cochleae were dissected and immersed in 1 μM FM 1-43FX (PA1-915, ThermoFisher) dissolved in HBSS (ThermoFisher) for 10 s at room temperature in the dark. Cochleae were rinsed three times with HBSS and placed in 100 μl Cell Recovery Solution (354253, Discovery Labware) for 10 min at 37 °C, then transferred to 100 μl TrypleE Express Enzyme (12604013, ThermoFisher). Sensory epithelia were extracted by forceps. After incubation for 10 min at 37 °C, the tissues were pipetted up and down 30 times. FM 1-43-positive cells were isolated using a 1-μl pipette under a microscope (Axiovert 200M, Carl Zeiss), then subjected to whole-genome amplification by MALBAC Single Cell WGA Kit (YK001A, Yikon Genomics). Statistical analysis. Statistical analyses were performed by two-way ANOVA with Bonferroni corrections for multiple comparisons for ABRs, DPOAEs, and acoustic startle response; and by Student's t-test for hair cell transduction currents using Prism 6.0 (GraphPad). No statistical methods were used to predetermine sample size. A total of 106 Tmc1
Bth/+ or C3H mice (P0-2) of either sex were used for injections. The mice were randomly assigned to the different experimental groups. The final 25% of the experiments were performed in a double-blinded manner. Code availability. Labview software for cochlear function testing is available here: http://www.masseyeandear.org/research/otolaryngology/investigators/laboratories/eaton-peabody-laboratories/epl-engineering-resources. Matlab scripts used to quantify the acoustic startle response are available from the corresponding authors on request. Indel identification scripts are provided in the Supplementary Information. Data availability. High-throughput sequencing data have been deposited in the NCBI Sequence Read Archive database under accession code SRP103108. All other data are available from the corresponding authors on reasonable request. 5) or Tmc1 Bth (lanes 6-10) with 300 nM of each of the four Cas9-sgRNAs shown for 15 min at 37 °C. Expected cleavage products are 774-778 bp and 217-221 bp. M, 100-bp ladder; the lower two heavy bands are 500 and 1,000 bp. b, Quantification of DNA cleavage in a by densitometry using imageJ. c, Comparison of transfection efficiency in HEK293T cells and wild-type primary fibroblasts. Fifty nanograms GFP plasmid, 10 nM Cas9-FitC-Tmc1-mut3 sgRNA RNP, or 10 nM Cas9-CrRNA-Tmc1-mut3-atto-550-TracrRNA RNP were delivered into HEK293T cells or wild-type primary fibroblasts using 3 μl Lipofectamine 2000. For samples with GFP plasmid, the fraction of GFP-positive cells was measured by flow cytometry 24 h after delivery. For samples with Cas9-FitC-Tmc1-mut3 RNP or Cas9-CrRNA-Tmc1-mut3-atto-550-TracrRNA RNP, medium was removed 6 h after delivery. The cells were trypsinized, washed three times with 500 μl PBS containing 20 U ml −1 heparin, and subjected to flow cytometry. d, Wild-type or Bth mutant Tmc1 allele editing in primary fibroblasts derived from wild-type or Tmc1
Bth/Bth mice as a function of the dose of Cas9-Tmc1-mut3-lipid complex. Cas9-Tmc1-mut3 (12.5, 25, 50, 100, 200, or 400 nM) was delivered into the primary fibroblasts using Lipofectamine 2000 in DMEM-FBS. e, Lipid-mediated delivery of Cas9-sgRNA complexes into primary fibroblasts derived from wild-type or Tmc1
Bth/Bth mice. We delivered 100 nM of purified Cas9 protein and each wild-type Tmc1-targeting sgRNA (Tmc1-wt1, Tmc1-wt2, or Tmc1-wt3) or Tmc1
Bth mutant-targeting sgRNA (Tmc1-mut1, Tmc1-mut2, or Tmc1-mut3) into wild-type fibroblasts (red) and Tmc1 Bth/+ mice. a, One thousand nanograms of Cas9 plasmid, 300 ng Tmc1-mut3 sgRNA plasmid, 400 ng pmaxGFP plasmid, and 50 pmol double-stranded oligodeoxynucleotides (dsODN) were nucleofected into Tmc1
Letter reSeArCH
Bth allele
Bth/+ fibroblasts using a LONZA 4D-Nucleofector. Genomic DNA was extracted 96 h after nucleofection and subjected to GUIDE-seq as previously described 23 . Off-T1 to Off-T10 are ten off-target sites detected by GUIDE-seq. Mismatches compared to the on-target site are shown and highlighted in colour. The Tmc1 Bth allele targeted by sgRNA Tmc1-mut3 is shown in the top row. b, Indel frequency at the Tmc1 locus and at each of the off-target loci in Cas9-Tmc1-mut3-treated Tmc1
Bth/Bth primary fibroblasts following plasmid DNA nucleofection or following RNP delivery. For RNP delivery, 100 nM Cas9-Tmc1-mut3 RNP was delivered to the Tmc1 Bth/Bth fibroblasts using 3 μl Lipofectamine 2000. Indels were detected by HTS at the Tmc1 ontarget site and at each off-target site. Red, samples nucleofected with DNA plasmids encoding Cas9 and Tmc1-mut3 sgRNA; blue, samples treated with Cas9-Tmc1-mut3 RNPs; grey, control samples nucleofected with unrelated dsDNA only. Extended Data Figure 4 | Cas9-Tmc1-mut3-lipid injection reduces hearing loss, improves acoustic startle response, and preserves stereocilia in Tmc1 Bth/+ mice. a, Phalloidin labelling showed the preservation of stereocilia of IHCs in an ear eight weeks after injection with Cas9-Tmc1-mut3 sgRNA at three frequency locations indicated, whereas the uninjected contralateral inner ear of the same mouse showed severe degeneration of stereocilia at locations corresponding to 16 and 32 kHz. The boxes indicate the stereocilia, which are shown at the bottom of each image at higher magnification. Scale bars, 10 μm. Similar results were observed in other injected ears that were immunolabelled (n = 5). b, Representative ABR waveforms showing reduced threshold (red traces) at 16 kHz in a Cas9-Tmc1-mut3-lipid-injected Tmc1
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Bth/+ ear (left) compared to the uninjected contralateral ear (right) of the same mouse after four weeks. c, Eight weeks after Cas9-Tmc1-mut3 injection into Tmc1
Bth/+ ears (blue), mean ABR thresholds were significantly reduced at three frequencies. Uninjected Tmc1 Bth/+ ears (red) showed ABR thresholds >85 dB at all frequencies after eight weeks. ABR thresholds from wild-type C3H mice are shown in green. d, ABR wave 1 amplitudes following 90 dB SPL stimulation at 16 kHz were greater in injected Tmc1
Bth/+ ears than in uninjected ears eight weeks after treatment. Individual values (n = 15 or 20 for uninjected, and 24 for injected) are shown; horizontal bars represent mean values. e, Startle responses at 16 kHz in individual Cas9-Tmc1-mut3 sgRNA-injected mice (blue) were significantly stronger (P < 0.001) than in uninjected mice (red) eight weeks after treatment. Among the different frequencies assayed, the number of ears tested (n) varies within the range shown (Supplementary Table 2 ). Statistical analyses of ABR thresholds, amplitudes, and startle responses were performed by two-way ANOVA with Bonferroni correction for multiple comparisons: *P < 0.05, **P < 0.01, ****P < 0.0001. Values and error bars reflect mean ± s.e.m. weeks after injection were elevated compared with uninjected ears at three frequencies following treatment with Cas9-Tmc1-mut3 sgRNA (a), and were elevated at two frequencies following treatment with Cas9-Tmc1-wt3 sgRNA (b), Cas9-GFP sgRNA (c), or dCas9-Tmc1-mut1 sgRNA (d). e, Eight weeks after Cas9-Tmc1-mut3 sgRNA injection, DPOAE thresholds were elevated at three frequencies in the injected group. Mean DPOAE thresholds of untreated wild-type (WT) C3H mice at four weeks (a) or eight weeks (e) of age are also shown in purple. Statistical analysis of DPOAE thresholds was performed by two-way ANOVA with Bonferroni correction for multiple comparisons: **P < 0.01, ****P < 0.0001. Values and error bars reflect mean ± s.e.m. Among the different frequencies assayed, the number of ears tested (n) varies within the range shown (Supplementary Table 2 ). The elevation of DPOAE thresholds despite enhanced hair cell survival (Fig. 2d, g ) suggests that the surviving OHCs may not be fully functional. IHCs can respond to sound and excite auditory nerve fibres in the absence of OHC amplification, although at higher SPLs. Thus, an improvement in ABR thresholds and suprathreshold amplitudes can occur without concomitant DPOAE enhancement if the functional improvements are restricted to the surviving IHCs. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined.
For hair cell transduction current recording, a minimum of 6 hair cells (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) were recorded for each condition. In experimental groups to show reproducible and robust hearing, we used a minimum of 11 animals (from 11 to 30) for each of the frequency studied. For auditory startle evaluation, we used 9 injected animals to better measure the response and variations, and used 5 uninjected control animals due to their uniform unresponsiveness. We used a minimum of 4 animals in all control studies. Other experiments were done in biological triplicate, n=3 on different days. In previous studies we determined this sample size to be sufficient to ensure reproducibility.
Data exclusions
Describe any data exclusions. For ABR measurements, a small fraction of frequencies for which thresholds were not apparent were excluded to ensure that only ABR thresholds scored accurately were used.
Replication
Describe whether the experimental findings were reliably reproduced.
All the experimental findings were replicated with the number of replicates, animals and variations shown by n, SD (in vitro assays), and SEM (in vivo experiments).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The animals of the same genotypes (Bth/+ or C3H) were randomly chosen to be in experimental or control groups according to experimental design.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All data from in vivo experiments were collected and analyzed by at least two researchers who were both blinded to experiment.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Prism 6 from GraphPad was used for statistic analysis. Matlab were used for indelidentification and acoustic startle reflex data analyses. ImageJ (NIH image) was used for IHC and OHC counting. Adobe Photoshop CS3 was used to composite images showing the whole cochlea. Custom LabVIEW software controlling National Instruments 24-bit soundcards (6052E) generated all ABR/DPOAE stimuli and recorded all responses.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
